Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B by 諛뺤��슜 et al.
Copyright © 2013 by The Korean Association for the Study of the Liver
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 2287-2728      
eISSN 2287-285X
http://dx.doi.org/10.3350/cmh.2013.19.4.399
Clinical and Molecular Hepatology 2013;19:399-408Original Article
Performance evaluation of the HepB Typer-Entecavir kit 
for detection of entecavir resistance mutations in chron-
ic hepatitis B
Sang Hoon Ahn1,2,3*, Ji-Yong Chun4*, Soo-Kyung Shin4, Jun Yong Park1,2, Wangdon Yoo4, Sun Pyo Hong4, Soo-Ok Kim4, 
and Kwang-Hyub Han1,2,3
1Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul; 2Liver Cirrhosis Clinical 
Research Center, Seoul; 3Brain Korea 21 Project for Medical Science, Seoul; 4Research and Development Center, GeneMatrix Inc., 
Seongnam, Korea
Corresponding author : Soo-Ok Kim
Research and Development Center, GeneMatrix Inc., KOREA BIO PARK, 
700 Daewangpangyo-ro, Bundang-gu, Seongnam 463-400, Korea
Tel. +82-31-628-2088, Fax. +82-31-628-2001
E-mail; sookim@genematrix.net
Abbreviations: 
ADV, adefovir; CHB, Chronic hepatitis B; ETV, entecavir; HBV, Hepatitis 
B virus; HCC, Hepatocellular carcinoma; LMV, lamivudine; MALDI-
TOF, matrix-assisted laser desorption ionization time-of-flight; RFMP, 
restriction fragment mass polymorphism 
*These authors made an equal contribution to this work.
Received : Sep. 25, 2013 /  Revised : Oct. 31, 2013 /  Accepted : Nov. 7, 2013
Background/Aims: Molecular diagnostic methods have enabled the rapid diagnosis of drug-resistant mutations in 
hepatitis B virus (HBV) and have reduced both unnecessary therapeutic interventions and medical costs. In this study 
we evaluated the analytical and clinical performances of the HepB Typer-Entecavir kit (GeneMatrix, Korea) in detecting 
entecavir-resistance-associated mutations. 
Methods: The HepB Typer-Entecavir kit was evaluated for its limit of detection, interference, cross-reactivity, and 
precision using HBV reference standards made by diluting high-titer viral stocks in HBV-negative human serum. The 
performance of the HepB Typer-Entecavir kit for detecting mutations related to entecavir resistance was compared 
with direct sequencing for 396 clinical samples from 108 patients. 
Results: Using the reference standards, the detection limit of the HepB Typer-Entecavir kit was found to be as low 
as 500 copies/mL. No cross-reactivity was observed, and elevated levels of various interfering substances did not 
adversely affect its analytical performance. The precision test conducted by repetitive analysis of 2,400 replicates with 
reference standards at various concentrations showed 99.9% agreement (2398/2400). The overall concordance rate 
between the HepB Typer-Entecavir kit and direct sequencing assays in 396 clinical samples was 99.5%. 
Conclusions: The HepB Typer-Entecavir kit showed high reliability and precision, and comparable sensitivity and 
specificity for detecting mutant virus populations in reference and clinical samples in comparison with direct 
sequencing. Therefore, this assay would be clinically useful in the diagnosis of entecavir-resistance-associated 
mutations in chronic hepatitis B. (Clin Mol Hepatol 2013;19:399-408)
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INTRODUCTION 
Despite the availability of highly effective and safe vaccines for 
more than 20 years, more than 400 million individuals worldwide 
are chronically infected with hepatitis B virus (HBV).1 Chronic hep-
atitis B (CHB) infection is associated with the development of cir-
rhosis, hepatocellular carcinoma (HCC), and death.2,3 Approxi-
mately 25% of patients with HBV will eventually die of liver failure 
and hepatocellular carcinoma if left untreated. In the REVEAL 
study, the most significant risk factor for the development of cir-
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rhosis or HCC was directly proportional to serum HBV DNA lev-
els,4-6 and it appears that the sustained suppression of serum HBV 
DNA replication is essential for impeding or reversing disease pro-
gression. Hence, an effective and prolonged suppression of HBV 
DNA, which reduces the risk of cirrhosis and HCC, is the primary 
treatment target. Antiviral therapy is used in CHB to minimize liver 
damage and limit disease progression.7
The roadmap concept was established by Keeffe et al.8 Early 
monitoring of virological responses to therapy in CHB treated with 
oral nucleos(t)ide analogs (NAs) is essential to identify primary 
treatment failure at week 12 and suboptimal responses at week 
24 in order to modify the management accordingly. NAs can func-
tion as antiviral agents by inhibiting HBV replication and compet-
ing with the natural nucleotide substrate of DNA polymerase, 
thereby terminating the synthesis of viral DNA.9 However, it also 
often results in the emergence of drug resistant mutants and an 
ensuing treatment failure.
The deoxyguanosine nucleoside analogue entecavir (ETV) has 
been shown to be highly effective at suppressing HBV DNA repli-
cation to undetectable levels and normalizing alanine aminotrans-
ferase (ALT) in the treatment of patients with chronic hepatitis B,10-
16 including patients with advanced fibrosis or cirrhosis and 
compensated liver disease.17,18 In vitro studies have shown that 
ETV is effective in suppressing adefovir (ADV) resistant mutants.19 
ETV has been reported to be effective in suppressing HBV DNA 
levels in ADV resistant patients with prior lamivudine (LMV) resis-
tance.20 ETV monotherapy may be considerably efficacious in cas-
es with an initial virological response but its efficacy is attenuated 
by frequent emergence of ETV resistance in ADV refractory CHB 
patients with prior LMV resistance.21
The routine use of genotypic drug resistance testing requires 
convenient assays with high reproducibility that can be performed 
by laboratories skilled in molecular diagnostic techniques. The 
HepB Typer-Entecavir kit, which has recently acquired the Korea 
Food and Drug Safety (KFDA) approval for in vitro diagnostic use, 
is designed to provide mutant information of the codons 184, 202 
and 250 in the polymerase (reverse transcriptase, rt) coding region 
by using restriction fragment mass polymorphism (RFMP) which is 
based on amplification and mass detection of oligonucleotides ex-
cised from type IIS enzyme digestion using matrix-assisted laser 
desorption ionization time-of-flight (MALDI-TOF) mass spectrometry.
 In order to determine the effects of specimen characteristics on 
the performance characteristics of the HepB Typer-Entecavir kit, a 
series of studies were undertaken to assess the effect of concen-
trations of HBV DNA, presence of interfering substances, and oth-
er viral nucleotides. Ability to detect drug resistance-associated 
mutations was also evaluated using a HBV DNA samples derived 
from molecular clones carrying a variety of resistance associated 
mutations in codons rt184, rt202 and rt250 and the assay perfor-
mance was compared with results from direct sequencing assays.
MATERIALS AND METHODS
Patients
This study included 396 specimens stored in Yonsei Liver Blood 
Bank (YLBB) collected from 108 patients with chronic HBV infec-
tion who visited Severance Hospital, Seoul, Korea between Febru-
ary 2008 and June 2011. 
Patients eligible for entry to the study were aged ≥20 years 
with serum HBV surface antigen (HBsAg) present ≥6 months and 
HBeAg-positive CHB being treated with LMV for ≥6 months. Eligi-
ble patients with partial virologic response or resistance against 
LMV receive ETV 0.5 mg or 1mg for ≥6 months, respectively. The 
upper limit of normal (ULN) for ALT was defined as 40 IU/L. Eligi-
ble patients had ALT <10×ULN with no evidence of HCC. All pa-
tients were tested for ETV mutations at baseline and at weeks 24, 
48 and 72 in patients with serum HBV DNA≥60 IU/mL. Patients 
were excluded from this study if they had serological evidence of 
coinfection with HCV, HIV or hepatitis D virus. Those with decom-
pensated liver disease, pregnant and breastfeeding women were 
also excluded. Experimental protocol followed the ethical guide-
lines of the 1975 Declaration of Helsinki, as reflected in a priori in-
stitutional review board approval. All the patients gave signed in-
formed consent.
Serum specimens
In total, 396 serum specimens from 108 patients were taken 
and stored at -70°C as 1 mL aliquots until use. Specimens were 
shipped on dry ice to the testing laboratories, where they were 
again stored at -70°C. HBV DNA was extracted from 200 μL of 
serum specimens using the QIAamp blood kit (Qiagen, 
Chatsworth, CA, USA) according to the manufacturer’s instruc-
tions and dissolved in 20 μL of distilled water. 2 μL of the viral 
DNA was used for the PCR reaction, HBV DNA titer was quantified 
using COBAS AmpliPrep-COBAS TaqMan (detection limit: 20 IU/
mL; Roche Diagnostics GmbH, Mannheim, Germany). 226 serum 
specimens were diagnosed with HBV DNA positive on the basis of 
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HBV DNA titer (≥60 IU/mL). Among these specimens, 102 speci-
mens had rt204M, and 124 specimens had rtM204I/V. Other 170 
serum specimens were diagnosed with HBV DNA negative (HBV 
DNA <60 IU/mL). HBV negative human serum was purchased 
from a commercial source (Boston Biomedica, Inc., Cambridge, 
MA, USA).
Preparation of reference standards
Plasmids with type-specific inserts of the wild type and ETV re-
sistance mutant viruses, which obtained from serum specimens 
collected from the HBV infected subjects or prepared by site-di-
rected mutagenesis of a molecular clone, were cloned into the 
pCR-Script Amp cloning vector (Stratagene, La Jolla, CA, USA) and 
used for assessing the analytical performance of the HepB Typer-
Entecavir kit. International standard for HBV DNA (PHD801, Sera-
Care, Gaithersburg, MD, USA) was purchased from SeraCare for 
calibrating the concentration of the reference standards. Muta-
tions were introduced into the codons rt184, rt202 and rt250 us-
ing the Altered Sites II in vitro mutagenesis system (Promega, 
Madison, Wi, USA). Representative test results of the HepB Typer-
Entecavir kit and direct sequencing were presented in supplemen-
tary Figure 1.
Substances for the interference test
To examine the effects of different interfering substances that 
might be present during use of the HepB Typer-Entecavir kit on its 
performance, test DNA samples in HBV negative human serum 
were spiked with anticoagulants (wafarin, heparin, EDTA, or sodi-
um citrate), antiplatelet agent (aspirin, ticlopidine), anticoagulants-
preservatives (acid citrate dextrose (ACD), citrate phosphate dex-
trose (CPD), or citrate phosphate dextrose with adenine (CPDA)), 
antiviral compounds (adefovir, lamivudine, or entecavir), or DNA 
extraction agent (ethanol; test concentration is 5% and 10%, re-
spectively).
Viruses for cross-reaction evaluation
To evaluate potential cross-reaction, human papillomavirus 
(HPV), herpes simplex virus (HSV) 1, HSV-2, and human T-lympho-
tropic virus (HTLV) were obtained from American Type Culture 
Collection (ATCC). Hepatitis C virus (HCV), hepatitis A virus (HAV), 
adenovirus, and varicella zoster virus (VZV) were obtained from 
National Institute for Biological Standards and Control (NIBSC). 
Human immunodeficiency virus (HIV) was obtained from SeraCare. 
Viral DNA was determined quantitatively by a branched DNA 
(bDNA) assay (VersantTM 3.0; Bayer Healthcare LLC Diagnostic Di-
Figure 1. Comparison of the results of the HepB Typer-Entecavir kit and direct sequencing assays for detecting mixed genotypes. Sera were 
taken from patients infected with HBV and carrying entecavir resistance mutations, and examined using the HepB Typer-Entecavir kit and direct 
sequencing assays. (A) Molecular masses of 2769.2/3101.0 and 3046.7 represent Thr (ACT) and Leu (CTT) of codon rt184, respectively. However, 
the direct sequencing assay determined only the Thr (ACT) of codon rt184 in the clinical samples. Molecular mass of 4032.2 represents Ser (AGT) 
of codon rt202. Molecular masses of 3645.5/3755.9 represent Met (ATG) of codon rt250. Each codon is indicated by a red box in the sequencing 
chromatogram. AI, absolute intensity; m/z, mass-to-charge ratio.
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vision, Tarrytown, NY, USA), which has a detection limit of 2,000 
copies/mL. To test the effect of other viral sequences on perfor-
mance of HepB Typer-Entecavir kit, some test DNA samples in 
HBV negative human serum were spiked with HPV, HSV-1, HSV-2, 
HTLV, HCV, HAV, Adenovirus, VZV, or HIV (50,000 copies/mL, re-
spectively).
Precision evaluation
The test was conducted by 20-day consecutive analysis of each 
24 replicates with two concentration HBV samples (1,500 and 
50,000 copies/mL) for determination of intra-day and inter-day 
precision. The 24-replicate comprises 2 independent runs more 
than 4 hours apart of two-replicates performed by 3 operators in 
two laboratories (Genematrix, Inc. Yongin lab. and Genematrix, 
Inc. Seongnam lab.).
RFMP and direct sequencing analyses for test-
ing HBV ETV resistance mutations
Genotypic analysis of HBV ETV-resistant mutations (rt184, 
rt202, and rt250) was performed using the HepB Typer-Entecavir 
kit according to the manufacturer’s recommendations, (GeneMa-
trix, Inc., Korea) similar as previously described.22,23 As summarized 
in Supplementary Table 1, the released diagnostic fragments from 
enzymatic digestion consist of unique sizes for codons rt184, 
rt202, and rt250 leading to easy identification of sequence varia-
tion in multiple codons in a single mass spectrum. The genotypic 
analysis by HepB Typer-Entecavir kit was compared with direct se-
quencing analysis. Direct sequence analysis was performed by ABI 
PRISM 310 Genetic Analyzer (Applied Biosystems, New York, NY, 
USA) and HBV genotype was assigned by web-based NCBI retro-
viruses genotyping analysis of the obtained sequences (http://
www.ncbi.nlm.nih.gov/projects/genotyping). All tested samples 
were genotype C.
Statistical analysis
A limit of detection test was performed by probit analysis to 
compare sensitivity between the RFMP and direct sequencing as-
says using the statistical package SPSS version 13 (SPSS Inc., Chi-
cago, IL, USA).
RESULTS
Assessing the lower limit of detection
HBV negative serum samples spiked with HBV reference stan-
dard from a molecular clone of the wild type and ETV resistance 
mutant HBV to yield final concentrations of 5, 50, 500, 5,000, and 
50,000 HBV DNA copies/ml were used to assess the lower limit of 
detection of the HepB Typer-Entecavir kit. Analysis of the dilution 
series of wild and mutant type HBV reference standard revealed 
detection limits of 490.91 and 499.12 copies per ml, respectively 
by Probit analysis (Table 1).
Table 1. Limit of detection of the HepB Typer-Entecavir kit
Type Copies/mL Detected/Tested
Observed Positive Hit 
Rates
Limit of detection 
(copies/mL) (95% CI)
Wild type 50,000 20/20 100%
490.91 (253.57-2129.02)
5,000 20/20 100%
500 19/20 95%
50 5/20 25%
5 0/20 0%
Mutant type 50,000 20/20 100%
499.12 (272.85-1795.47)
(rtT184L+rtS202G+rtM250V) 5,000 20/20 100%
500 19/20 95%
50 3/20 15%
 5 0/20 0%
Defined dilutions of HBV reference standard of the wild and mutant types in human genomic DNA backgrounds were made from 
50,000 copies to 5 copies per mL and analytical sensitivities were calculated by Probit analysis at a 95% detection level. Calculated 
sensitivity was expressed as copies/mL.
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Effect of interfering substances
To determine the effect of different interfering substances on 
assay performance, serum samples containing HBV reference stan-
dards at a titer of 1,500 copies/mL were spiked with a wafarin, 
heparin, EDTA, sodium citrate, aspirin, ticlopidine, ACD, CPD, 
CPDA, adefovir, lamivudine, entecavir or ethanol as described in 
Materials and Methods. For each sample, HepB Typer-Entecavir kit 
data from samples spiked with the various interfering substances 
were compared to the non-spiked samples. Each biochemical was 
tested in triplicate. None of the HBV-negative samples spiked with 
a potentially interfering substance gave a false-positive test result. 
No negative impact of elevated levels of various interfering sub-
stances was observed except the heparinized samples and 20% 
ethanol spiked samples (Table 2).
Cross-reaction evaluation
To determine the effect of clinically relevant viruses on assay 
performance, serum samples with or without HBV reference stan-
Table 3. Evaluation of cross-reactions of the HepB Typer-Entecavir kit
Viruses
HBV-negative 
Concordance (%)*
Wild type  
Concordance (%)*
Mutant type 
Concordance (%)*
Human papillomavirus (HPV) (ATCC 45113D) 100 100 100 
Hepatitis C virus (HCV) (NIBSC 08/264) 100 100 100 
Human immunodeficiency virus (HIV) (SeraCare PRD250-1.0) 100 100 100 
Herpes simplex virus (HSV) 1 (ATCC VR-539) 100 100 100 
Herpes simplex virus (HSV) 2 (ATCC VR-540) 100 100 100 
Hepatitis A virus (HAV) (NIBSC 00/560) 100 100 100 
Human T-lymphotropic virus (HTLV) (ATCC 45134D) 100 100 100 
Adenovirus (NIBSC 08/114) 100 100 100 
Varicella zoster virus (TypeB) (NIBSC 08/310) 100 100 100 
*Three times tested.
Table 2. Effects of interfering substances on the HepB Typer-Entecavir kit
Interfering substances
Wild type Mutant type
Concentration Concordance (%)* Concentration Concordance (%)*
Anticoagulants
Wafarin 5%, 10% 100 5%, 10% 100 
Heparin 5%, 10% 0 5%, 10% 0 
EDTA 5%, 10% 100 5%, 10% 100 
Sodium citrate 5%, 10% 100 5%, 10% 100 
Anti-platelet agents
Aspirin 5%, 10% 100 5%, 10% 100 
Ticlopidine 5%, 10% 100 5%, 10% 100 
Preservatives
Acid-citrate-dextrose (ACD) 5%, 10% 100 5%, 10% 100 
Citrate-phosphate-dextrose (CPD) 5%, 10% 100 5%, 10% 100 
Citrate-phosphate-dextrose with 
adenine (CPDA)
5%, 10% 100 5%, 10% 100 
Hepatitis treatment
Adefovir 5%, 10% 100 5%, 10% 100 
Lamivudine 5%, 10% 100 5%, 10% 100 
Entecavir 5%, 10% 100 5%, 10% 100 
Extraction reagents
Ethanol 5%, 10% 100 5%, 10% 100 
Ethanol >20% 0 >20% 0
*Three times tested.
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dard (50,000 copies/mL) were spiked with HPV, HSV-1, HSV-2, 
HTLV, HCV, HAV, adenovirus, VZV, or HIV as described in Materi-
als and Methods. Each pathogen was tested in triplicate. None of 
the HBV-negative samples spiked with clinically relevant viruses 
gave a false positive test result. None of clinically relevant viruses 
affected the HBV-positive samples, irrespective of wild and mu-
tant genotypes (Table 3). 
Precision evaluation
The precision test was conducted by 20-day consecutive analy-
sis at two concentration HBV samples (1,500 and 50,000 copies/
mL) of each 24 replicates comprising 2 independent runs of two-
replicates performed by 3 operators in 2 laboratories. Precision 
values were calculated from precision (%) = [(number of true posi-
tive + number of true negative)/total sample number] ×100. As 
shown in Table 4, the total precision conducted by the four refer-
ence standards was 99.9%, showing that the HepB Typer-Enteca-
vir kit method has highly reliable reproducibility and repeatability 
(Table 4).
Comparison of RFMP and direct sequencing 
assays for HBV ETV resistance mutations
All 396 clinical samples from 108 patients were analyzed by the 
HepB Typer-Entecavir kit and direct sequencing assays. Codons 
rt184, rt202 and rt250 were analyzed for the presence of ETV re-
sistance mutations. In the 170 HBV negative specimens (HBV DNA 
<60 IU/mL), both assays showed HBV DNA negativity in all sam-
ples tested. In the 226 HBV DNA positive specimens, the HepB 
Typer-Entecavir kit detected mutant virus with codons rt184, rt202 
and rt250 in 0.4% (1/226), 0.4% (1/226) and 0.9% (2/226) of the 
sera, respectively. In a total of 396 tested serum specimens, the 
overall concordance rates were 99.5% between the HepB Typer-
Entecavir kit and direct sequencing assays. Concordance rates 
were 99.7% (395/396) at codon rt184, 99.7% (395/396) at codon 
rt202, and 100% (396/396) at codon rt250 (Table 5), respectively. 
Both assays showed identical base substitution and amino acid 
composition in these positions. Compatible rates were observed 
0.3% (1/396) at codons rt184 and rt202, respectively. Two com-
patible cases, codons rt184 and rt202 mutant harboring patients, 
had rtM204I/V mutations with HBV DNA level of 1,190 and 7,720 
copies/mL, respectively. In this case, HepB Typer-Entecavir kit de-
tected more mixture samples than direct sequencing assay. This 
sample (mixed-type) at codon rt184 containing double mutations Ta
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in single codon was identified only by HepB Typer-Entecavir kit, as 
a result of the inability of the direct sequencing assay to determine 
the only wild type in the clinical samples. As shown in Figure 1, 
rt184T/L mixtures detected by HepB Typer-Entecavir kit could be 
scored as only rt184T (ACT) by direct sequencing. Of these, the 
HepB Typer-Entecavir kit showed a superior ability for detecting 
minor virus populations compared with direct sequencing. Overall, 
HepB Typer-Entecavir kit had 99.5% agreement with direct se-
quencing when only the detection of mutant virus was considered 
(Table 5).
DISCUSSION
Multi-drug resistance to LMV and ADV is becoming prevalent 
due to sequential treatment of LMV followed by ADV. ETV displays 
antiviral activity against both LMV-resistant and ADV-resistant 
HBV.19,24,25 A previous study showed that 79% of LMV-resistant 
patients had undetectable HBV DNA levels by bDNA assay at 24 
weeks of ETV therapy and that HBV DNA was undetectable by 
PCR assay in 26% of patients at 48 weeks.11 These results suggest 
a low response to ETV in patients with LMV resistance and in 
those with a limited response to ADV. As a consequence, ETV-re-
sistance mutations analysis may be a major tool both for clinicians 
to monitor treatment and for researchers to consequences for dis-
ease outcome.
HepB Typer-Entecavir kit exploits differences in the molecular 
masses of oligonucleotides comprising the ETV resistance varia-
tions in rt region. RFMP assay, which used in HepB Typer-Entecavir 
kit, is based on mass spectrometric analysis of small DNA frag-
ments, including sites of mutation.22,23,26-33 Mass spectrometry as-
sesses directly the mass of the PCR product, whereas other tech-
nologies only measure indirectly PCR products, either through 
hybridization or by sequencing reactions, which use PCR products 
as templates. Procedures have been developed in which PCR 
products are used as templates to which oligonucleotide primers 
are hybridized, base-extended and then analyzed by mass spec-
trometry.34 These assays can be useful, but they fail to employ one 
of the key advantages of mass spectrometry that the analysis of 
PCR products can be direct. In HepB Typer-Entecavir kit, mass of 
PCR products is determined directly, rather than their identity be-
ing interpreted on the basis of fluorescent or radioactive reporter 
tags. Both DNA strands can be analyzed in parallel, providing a 
level of internal confirmation not achievable by other methods. 
The use of a type IIS restriction enzyme makes the assay indepen-
dent of restriction sites within the HBV genome and suitable for 
many different viral genotypes because these enzymes cleave 
DNA at a fixed distance from the recognition sites incorporated 
into the amplification primers.
The study reported here assessed the performance of the HepB 
Typer-Entecavir kit under a variety of analytical conditions. The 
detection limit of the HepB Typer-Entecavir kit was found to be as 
low as 500 copies/mL. Presence of anticoagulants, antiplatelet 
agent, anticoagulants-preservatives, antiretroviral compounds, or 
ethanol had no significant effect on the accuracy of the kit. As ex-
pected, samples anticoagulated with heparin gave negative re-
sults, most likely due to interference of heparin with the amplifica-
tion of HBV DNA.35,36 No significant difference in results was 
observed in the present study between samples anticoagulated 
with any anticoagulants except heparin. Nevertheless, careful at-
tention should be given to prompt specimen processing after 
blood collection in order to optimize assay results. Similarly, pres-
ence of other viruses including HPV, HSV-1, HSV-2, HTLV, HCV, 
HAV, Adenovirus, VZV, and HIV did not cross-reaction with the as-
say. The cross-reactivity test from samples spiked into clinically 
relevant viruses suggests that HepB Typer-Entecavir kit is eligible 
to co-infected patients. The precision test conducted by repetitive 
analysis of a total of 2,400 replicates with various concentrations 
Table 5. Comparison of results obtained using the HepB Typer-Entecavir kit and direct sequencing assays in 396 clinical specimens
Agreement
HepB Typer-Entecavir kit Direct sequencing
Number of specimens
rt184 rt202 rt250 rt184 rt202 rt250
Concordant (n=394) T S M T S M 221
T S M/L T S M/L 2
T S L T S L 1
- - - - - - 170*
Compatible (n=2) T/L S M T S M 1
 T S/G M T S M 1
*The number of HBV DNA negative serum specimens.
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of reference standards showed 99.9% agreement, demonstrating 
that the HepB Typer-Entecavir kit provide highly precise and repro-
ducible genotype results for HBV entecavir resistance mutation.
The performance of the HepB Typer-Entecavir kit for detecting 
mutations related to ETV drug-resistances was compared with di-
rect sequencing for 396 clinical samples from 108 HBV infected 
patients. The HepB Typer-Entecavir kit successfully identified ge-
notypic changes tested in clinical samples. The prevalence of ETV 
resistant mutations in our study was found to be 4.6% (5/108), 
similar to those reported in previous studies.37,38 Compared with 
direct sequencing, the HepB Typer-Entecavir kit exhibited 99.5% 
concordance (Table 5). Specially, the HepB Typer-Entecavir kit out-
performed direct sequencing for the detection of single and dou-
ble mutations in compatible samples. The HepB Typer-Entecavir kit 
detected more mutant viruses with codons rt184 (1/396) and 
rt202 (1/396) of the sera, suggesting high sensitivity of the HepB 
Typer-Entecavir kit in terms of detecting minority variants. Hence, 
the discrepancy among the two assays may be due to a lower sen-
sitivity of minor mutant of direct sequencing. However, a further 
study would be required to validate the improved ability to detect 
mutant virus of HepB Typer-Entecavir kit with more closely moni-
tored samples from increased subjects.
In the previous study, the ability of RFMP method to detect mi-
nor virus populations with the LMV, ADV and ETV resistant muta-
tions was superior to that of TRUGENE sequencing.39 All discor-
dance between the two assays related to the detection of 
additional viral mutation by HepB Typer-Entecavir kit, which was 
missed by direct sequencing. The minor populations shown in the 
RFMP were further confirmed by the clonal sequencing, the RFMP 
assay was in excellent agreement with clonal sequencing (data not 
shown). These results might have been caused by the different an-
alytical sensitivities of two assays. Viral breakthrough could not 
predict based only on the presence of the mutant virus and the re-
sults of this highly sensitive molecular method should be interpret-
ed carefully, as antiviral drugs could be effective despite the pres-
ence of mutants.39 A 5-fold predominance of the drug resistant 
mutants over wild-type virus was significantly associated with viral 
breakthrough.30 Therefore, the lack of ability to detect both the 
wild-type and mutant virus populations could be disadvantage. 
Direct sequencing generally cannot detect a minor virus popula-
tion that comprises <20% of the total population,40 whereas 
RFMP can detect a minor population that comprises only 1% of 
the total population.28 The previous study has reported that RFMP 
was superior to PCR-RFLP for distinguishing mixed populations in 
six of 40 patients 22 and in another study that RFMP indicated the 
presence of additional mutant virus populations compared to IN-
NO-LiPA HBV DR in four of 60 patients.28
In summary, the HepB Typer-Entecavir kit which has recently ac-
quired KFDA approval for in vitro diagnostic use showed the ro-
bust analytical performance as well as capability of reliably and 
reproducibly detecting the entecavir resistance mutations includ-
ing codons rt184, rt202 and rt250 in clinical samples. Therefore, 
this assay would be clinically useful in diagnosis of entecavir resis-
tance-associated mutations in chronic hepatitis B.
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